Cargando…

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

K-ras mutations are major genetic events that drive cancer development associated with aggressive malignant phenotypes, while expression of the immune checkpoint molecule PD-L1 plays a key role in cancer evasion of the immune surveillance that also profoundly affects the patient outcome. However, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glorieux, Christophe, Xia, Xiaojun, He, Yong-Qiao, Hu, Yumin, Cremer, Kelly, Robert, Annie, Liu, Junchen, Wang, Fen, Ling, Jianhua, Chiao, Paul J., Huang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658718/ https://www.ncbi.nlm.nih.gov/pubmed/33171331 http://dx.doi.org/10.1016/j.redox.2020.101780

Ejemplares similares

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
por: Riccardo, Federica, et al.
Publicado: (2020)

Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells
por: Glorieux, Christophe, et al.
Publicado: (2019)

Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer
por: Wang, Peng, et al.
Publicado: (2015)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

K-Ras Binds Calmodulin-Related Centrin1 with Potential Implications for K-Ras Driven Cancer Cell Stemness
por: Manoharan, Ganesh babu, et al.
Publicado: (2023)

Malignant transformation by oncogenic K‐ras requires IDH2‐mediated reductive carboxylation to promote glutamine utilization
por: Liu, Rui, et al.
Publicado: (2022)

PLA2G2A Phospholipase Promotes Fatty Acid Synthesis and Energy Metabolism in Pancreatic Cancer Cells with K-ras Mutation
por: Zhang, Mingquan, et al.
Publicado: (2022)

Activation of RAS family members confers resistance to ROS1 targeting drugs
por: Cargnelutti, Marilisa, et al.
Publicado: (2014)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells
por: Meng, Ning, et al.
Publicado: (2019)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation
por: Jeon, So Mi, et al.
Publicado: (2022)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

ROS regulation of RAS and vulva development in Caenorhabditis elegans
por: Kramer-Drauberg, Maximilian, et al.
Publicado: (2020)

The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1
por: Nguyen, P T, et al.
Publicado: (2013)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder
por: Ahmad, Imran, et al.
Publicado: (2011)

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy
por: Lee, Soohyeon, et al.
Publicado: (2011)

Molecular genetics and cellular events of K-Ras-driven tumorigenesis
por: Jinesh, G G, et al.
Publicado: (2018)

Targeting K-Ras and apoptosis-driven cellular transformation in cancer
por: Godwin, Isha, et al.
Publicado: (2021)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1
por: Coetzee, Abigail S., et al.
Publicado: (2022)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications
por: Ferro, Elisa, et al.
Publicado: (2012)

NO, ROS, RAS, and PVAT: More Than a Soup of Letters
por: Barp, Clarissa Germano, et al.
Publicado: (2021)

TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway
por: Biswas, Polash Kumar, et al.
Publicado: (2022)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment
por: Gao, Chenggang, et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Human Mut T homolog 1 (MTH1): A roadblock for the tumor-suppressive effects of oncogenic RAS-induced ROS
por: Rai, Priyamvada
Publicado: (2012)

PD‐L1/PD‐L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK
por: Cao, Yihui, et al.
Publicado: (2022)

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018)

MiR‐3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway
por: Kong, Shiqi, et al.
Publicado: (2020)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_919fm3846unhc0brriv5ghagnq